PEPTIDES: THE 2026 FDA CRACKDOWN CONTROVERSYWhy this is MASSIVE SEO RIGHT NOW BPC 157 banned Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions Industry Update: Interim 503A and 503B Bulks Lists New Revisions FDA Peptide Reclassification 2026: What Researchers Want Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #